BioTuesdays

Tag - Ladenburg Thalmann

Ladenburg starts Aadi Bioscience at buy; PT $51

Ladenburg Thalmann launched coverage of Aadi Bioscience (NASDAQ:AADI) with a “buy” rating and price target of $51. The stock closed at $27.96 on Sept. 13. Aadi is a clinical-stage biotechnology company with a single...

Ladenburg starts Tryp Therapeutics at buy; PT $2

Ladenburg Thalmann initiated coverage of Tryp Therapeutics (OTCQB:TRYPF; CSE:TRYP) with a “buy” rating and $2 price target. The stock closed at 37 cents on Aug. 25. Tryp is focused on developing psychedelic...

Immutep Logo

Ladenburg starts Immutep at buy; PT $8.30

Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

Catabasis Pharma

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

Ladenburg starts Evaxion Biotech at buy; PT $23

Ladenburg Thalmann initiated coverage of Evaxion Biotech A/S (NASDAQ:EVAX) with a “buy” rating and $23 price target. The stock closed at $7.08 on March 1. Evaxion is a clinical-stage artificial intelligence (AI)...

Artelo Biosciences Logo

Ladenburg starts Artelo Biosciences at buy; PT $7

Ladenburg Thalmann initiated coverage of Artelo Biosciences (NASDAQ:ARTL) with a “buy” rating and price target of $7. The stock closed at $1.63 on Feb. 11. Artelo is developing first-in-class, proprietary therapeutics...

Ladenburg starts Viridian Therapeutics at buy; PT $40

Ladenburg Thalmann launched coverage of Viridian Therapeutics (NASDAQ:VRDN) with a “buy” rating and $40 price target. The stock closed at $21.78 on Jan. 22. Viridian’s lead asset, VRDN-001, is an anti-IGF-1R monoclonal...

Plus Therapeutics Logo

Ladenburg starts Plus Therapeutics at buy; PT $8

Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...

Tarsus Pharmaceuticals Logo

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...